Clinical Trial Update: Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immune response of the MSP1 42-C1 malaria vaccine with or without the CPG 7909 adjuvant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• CPG 7909 adjuvant (CpG oligodeoxynucleotide 7909)
• MSP1 42-C1 malaria vaccine (MSP1-42-C1)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Malaria | Phase 1 | Status: COMPLETED